Variant Bio Turns Five
<p>This fall will mark five years since <a href="https://www.variantbio.com/" rel="noopener ugc nofollow" target="_blank">Variant Bio</a> began its life as a genomic drug discovery company with a paradigm-changing mission — to fairly and ethically engage historically underrepresented populations in genomic research and use the resulting knowledge to develop life-saving therapeutics. In retrospect, that mission was ambitious on the part of myself, Stephane Castel, and Kaja Wasik, the scientific co-founders of the company. However, five years later, because of the hard work our team has put in, and the trust our partners and participating communities have placed in us, that mission no longer seems so far-fetched.</p>
<p>I’m extraordinarily proud of what we’ve accomplished to date and cannot wait to see what this next stage of the company will bring as we approach the clinic. At this point we’ve been able to take our findings from research around the world and move into the exciting next phase of drug discovery. We now have a pipeline with a program in lead optimization, getting us ever closer to the goal of delivering medicines to patients with diseases of great unmet medical need. In these last few years, we have also refined our priority therapeutic areas of interest to include inflammation-immunology, fibrosis, and kidney diseases. How did we come this far this fast, you might ask?</p>
<p><a href="https://medium.com/variantbio/variant-bio-turns-five-5f5eda61965"><strong>Website</strong></a></p>